Evidence Hub

Hafnia alvei Infections: Clinical Characteristics and Therapeutic Challenges of an Uncommon Pathogen

Herrera Parra JE, Antuña Montes L, Rodríguez Santiago SE, Gutiérrez Rodríguez J, López Álvarez EM, Burgos Bencosme N

Case reports in medicine, 2025

1 citation

Abstract

Hafnia alvei is a rare opportunistic pathogen of the Enterobacteriaceae family, typically regarded as a gastrointestinal commensal. However, it has been implicated in serious infections, particularly in immunocompromised patients, posing diagnostic and therapeutic challenges. We present the case of a 70-year-old woman with a history of cryptogenic cirrhosis postliver transplant, complicated by sepsis and advanced pancreatic adenocarcinoma under palliative care. She developed a urinary tract infection caused by Hafnia alvei and Klebsiella oxytoca, confirmed by cultures. Despite targeted antibiotic therapy with vancomycin and ciprofloxacin, her condition deteriorated, leading to death due to oncologic disease progression. This case underscores the pathogenic potential of Hafnia alvei, its role in polymicrobial infections, and the importance of antimicrobial susceptibility testing. Raising awareness of this under-recognized pathogen is crucial to improving outcomes in vulnerable populations.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free